for patients

Strategies of Development

Currently our studies focus on the large-scale production of recombinant human histone H1 derivatives for clinical studies of cancer. SymbioTec has developed its own biotechnological process to produce ONCOHIST, a derivative of human histone H1, which is provided by a bio-pharmaceutical contract-manufacturer in GMP quality for clinical studies. Acute myeloid leukemia (AML) was the first clinical indication to be chosen.

A pilot clinical Phase I/II study with AML patients has been conducted in the Saarland University’s hospital Homburg/Saar and proved that our drug ONCOHIST is well tolerated and gave already clear indications of clinical effects.

Clinical studies including other indications in the field of neoplastic diseases are envisaged. SymbioTec welcomes strategic alliances with internationally operating cooperation partners for the opening of markets in its central area, tumour therapy, as well as for the development of the diagnostic potential of histone-related medicaments.


read more on:
Intellectual property
The team
Cooperation